Editas Medicine Announces EDIT-401 As Lead In Vivo Candidate With ~90% LDL-C Reduction And Human Proof-of-Concept By 2026
Benzinga Newsdesk 1 year ago
News
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track for human proof-of-concept data by end of 2026Strong cash position with operational runway into second quarter of
- EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates
- EDIT-401 on track for human proof-of-concept data by end of 2026
- Strong cash position with operational runway into second quarter of 2027
- Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET